Wall Street brokerages expect Heron Therapeutics, Inc. (NASDAQ:HRTX – Get Rating) to report earnings of ($0.45) per share for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Heron Therapeutics’ earnings. The highest EPS estimate is ($0.30) and the lowest is ($0.56). Heron Therapeutics reported earnings of ($0.58) per share in the same quarter last year, which suggests a positive year over year growth rate of 22.4%. The firm is expected to report its next quarterly earnings results after the market closes on Monday, January 1st.
On average, analysts expect that Heron Therapeutics will report full-year earnings of ($1.59) per share for the current financial year, with EPS estimates ranging from ($2.18) to ($0.82). For the next financial year, analysts anticipate that the firm will report earnings of ($0.91) per share, with EPS estimates ranging from ($1.20) to ($0.40). Zacks’ EPS calculations are an average based on a survey of research analysts that cover Heron Therapeutics.
Heron Therapeutics (NASDAQ:HRTX – Get Rating) last issued its quarterly earnings results on Monday, February 28th. The biotechnology company reported ($0.54) EPS for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.05. The business had revenue of $20.66 million for the quarter, compared to analyst estimates of $25.77 million. Heron Therapeutics had a negative return on equity of 159.70% and a negative net margin of 255.58%. Heron Therapeutics’s quarterly revenue was up .2% compared to the same quarter last year. During the same period last year, the company posted ($0.68) earnings per share.
A number of institutional investors have recently bought and sold shares of HRTX. Zullo Investment Group Inc. purchased a new position in Heron Therapeutics during the fourth quarter worth about $30,000. Dark Forest Capital Management LP grew its position in Heron Therapeutics by 3,258.7% during the third quarter. Dark Forest Capital Management LP now owns 3,090 shares of the biotechnology company’s stock worth $33,000 after buying an additional 2,998 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. purchased a new position in Heron Therapeutics during the third quarter worth about $37,000. Russell Investments Group Ltd. purchased a new position in Heron Therapeutics during the fourth quarter worth about $39,000. Finally, Point72 Hong Kong Ltd grew its position in Heron Therapeutics by 241.1% during the third quarter. Point72 Hong Kong Ltd now owns 6,787 shares of the biotechnology company’s stock worth $73,000 after buying an additional 4,797 shares in the last quarter.
Shares of Heron Therapeutics stock opened at $4.11 on Friday. The business’s fifty day simple moving average is $5.39 and its 200 day simple moving average is $7.97. The company has a current ratio of 3.58, a quick ratio of 2.90 and a debt-to-equity ratio of 1.92. Heron Therapeutics has a 12 month low of $3.95 and a 12 month high of $18.80.
Heron Therapeutics Company Profile (Get Rating)
Heron Therapeutics, Inc, a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.
- Get a free copy of the StockNews.com research report on Heron Therapeutics (HRTX)
- ChemoCentryx: A Biotech Stock Well Worth the Risk
- Skechers Stock Can Be Bought on Pullbacks
- Nasdaq Stock is a Buy the (Deep) Dip Opportunity
- Three Stocks To Ride Out A Rough Market
- MarketBeat: Week in Review 5/2 – 5/6
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.